ACADIA Pharmaceuticals (ACAD) Competitors

$16.63
+0.32 (+1.96%)
(As of 03:28 PM ET)

ACAD vs. MLTX, MOR, EVO, SMMT, IDYA, JANX, INDV, ARWR, CRNX, and XENE

Should you be buying ACADIA Pharmaceuticals stock or one of its competitors? The main competitors of ACADIA Pharmaceuticals include MoonLake Immunotherapeutics (MLTX), MorphoSys (MOR), Evotec (EVO), Summit Therapeutics (SMMT), IDEAYA Biosciences (IDYA), Janux Therapeutics (JANX), Indivior (INDV), Arrowhead Pharmaceuticals (ARWR), Crinetics Pharmaceuticals (CRNX), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical preparations" industry.

ACADIA Pharmaceuticals vs.

MoonLake Immunotherapeutics (NASDAQ:MLTX) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to MoonLake Immunotherapeutics' net margin of -8.44%. ACADIA Pharmaceuticals' return on equity of -9.22% beat MoonLake Immunotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MoonLake ImmunotherapeuticsN/A -9.22% -9.00%
ACADIA Pharmaceuticals -8.44%-15.67%-9.15%

ACADIA Pharmaceuticals received 826 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 76.27% of users gave MoonLake Immunotherapeutics an outperform vote while only 73.07% of users gave ACADIA Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
MoonLake ImmunotherapeuticsOutperform Votes
45
76.27%
Underperform Votes
14
23.73%
ACADIA PharmaceuticalsOutperform Votes
871
73.07%
Underperform Votes
321
26.93%

MoonLake Immunotherapeutics has higher earnings, but lower revenue than ACADIA Pharmaceuticals. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MoonLake ImmunotherapeuticsN/AN/A-$36.01M-$0.76-55.97
ACADIA Pharmaceuticals$726.44M3.74-$61.29M-$0.38-43.39

In the previous week, ACADIA Pharmaceuticals had 5 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 10 mentions for ACADIA Pharmaceuticals and 5 mentions for MoonLake Immunotherapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.64 beat MoonLake Immunotherapeutics' score of -0.09 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MoonLake Immunotherapeutics
0 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ACADIA Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

MoonLake Immunotherapeutics currently has a consensus target price of $74.46, indicating a potential upside of 75.20%. ACADIA Pharmaceuticals has a consensus target price of $35.82, indicating a potential upside of 116.59%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than MoonLake Immunotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MoonLake Immunotherapeutics
0 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.75
ACADIA Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.80

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 15.3% of MoonLake Immunotherapeutics shares are held by insiders. Comparatively, 27.5% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

MoonLake Immunotherapeutics has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500.

Summary

ACADIA Pharmaceuticals beats MoonLake Immunotherapeutics on 10 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACAD vs. The Competition

MetricACADIA PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.72B$6.50B$4.84B$7.62B
Dividend YieldN/A3.07%2.96%3.93%
P/E Ratio-43.397.21170.8916.18
Price / Sales3.74301.152,457.4980.81
Price / CashN/A29.6846.2835.09
Price / Book6.275.974.754.38
Net Income-$61.29M$141.31M$103.00M$213.88M
7 Day Performance-1.96%0.32%0.60%1.73%
1 Month Performance-7.31%-9.53%-6.35%-3.87%
1 Year Performance-18.81%-2.61%9.63%9.06%

ACADIA Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MLTX
MoonLake Immunotherapeutics
3.1002 of 5 stars
$43.25
+5.4%
$74.46
+72.2%
+106.2%$2.76BN/A-56.9150Analyst Report
Positive News
MOR
MorphoSys
0.7424 of 5 stars
$18.04
+0.4%
$11.78
-34.7%
+254.1%$2.72B$257.89M-11.56524Upcoming Earnings
EVO
Evotec
2.4653 of 5 stars
$7.65
+3.9%
$14.00
+83.0%
N/A$2.71B$791.73M0.004,952Analyst Report
Short Interest ↓
Analyst Revision
SMMT
Summit Therapeutics
1.3255 of 5 stars
$3.73
+6.9%
$8.00
+114.5%
+161.0%$2.62B$700,000.00-2.44105Upcoming Earnings
Gap Up
IDYA
IDEAYA Biosciences
3.1161 of 5 stars
$39.02
+3.8%
$44.55
+14.2%
+107.2%$2.91B$23.39M-19.81124
JANX
Janux Therapeutics
3.7173 of 5 stars
$49.78
+1.8%
$61.33
+23.2%
+218.2%$2.57B$8.08M-37.1564Positive News
INDV
Indivior
2.7133 of 5 stars
$18.63
+0.5%
$36.00
+93.2%
N/A$2.57B$1.09B-931.031,164Short Interest ↑
News Coverage
Positive News
ARWR
Arrowhead Pharmaceuticals
3.7071 of 5 stars
$23.78
-0.6%
$53.45
+124.8%
-34.9%$2.96B$181.74M-8.55525Positive News
CRNX
Crinetics Pharmaceuticals
4.1259 of 5 stars
$44.22
+1.8%
$54.17
+22.5%
+127.7%$3.08B$4.01M-11.95290Upcoming Earnings
Short Interest ↑
XENE
Xenon Pharmaceuticals
2.6519 of 5 stars
$41.09
+2.7%
$59.44
+44.7%
+0.8%$3.10B$9.43M-15.11251Positive News

Related Companies and Tools

This page (NASDAQ:ACAD) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners